Market Access News | pharmaphorum

News

BMS’ Sotyktu cleared for NHS use in psoriasis

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.

News

FDA approves first cell therapy for type 1 diabetes

CellTrans has claimed the first FDA approval for a cell therapy used to treat type 1 diabetes, consisting of insulin-producing islet beta cells taken from deceased donors.

News

UCB stakes claim to gMG market as FDA clears Rystiggo

The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the company says is the only drug that can be u

News

NICE not convinced yet by Mounjaro for diabetes

Eli Lilly is riding high on new data for its experimental obesity therapies, but i

News

Jardiance is first SGLT2 given FDA OK for use in children

With rates of juvenile type 2 diabetes rocketing in the US, doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years.

News

CMS sheds light on its registry plan for Alzheimer’s drugs

The Centers for Medicare and Medicaid Services (CMS) in the US has provided more details about the controversial plan to require participation in a patient registry as a c

BMS’ Sotyktu cleared for NHS use in psoriasis

FDA approves first cell therapy for type 1 diabetes

UCB stakes claim to gMG market as FDA clears Rystiggo

NICE not convinced yet by Mounjaro for diabetes

Jardiance is first SGLT2 given FDA OK for use in children

CMS sheds light on its registry plan for Alzheimer’s drugs

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks